Mein Warenkorb

Human NY-ESO-1 TCR & CD3E & CD3D & CD3G & CD3Z Full Length Protein Complex (VLP)

User Reviews
Product Number/Spec
Price
Menge
NYZ-H5213-20ug
$620.00
NYZ-H5213-100ug
$1235.00
NYZ-H5213-500ug (250ug X 2)
$4305.00
NYZ-H5213-1mg (250ug X 4)
Inquiry
ETA of in-stock products:2 business days
Gesamtanzahl Product Amount$ 0

Product Details

  • Application

    1. Immunization
    2. Cell based assay (FACS or functional assay)
    3. Screening (ELISA)
  • Synonyms

    NY-ESO-1 TCR & CD3E & CD3D & CD3G & CD3Z

  • Source

    Human NY-ESO-1 TCR & CD3 Full Length Protein Complex (VLP) (NYZ-H5213) is expressed from human 293 cells (HEK293). It contains AA Asp 23 - Ile 207 & Phe 22 - Lys 171 & Gln 23 - Asn 182 & Gln 22 - Arg 164 (Accession # P07766-1 & P04234-1 & P09693-1 & P20963-1).

    Predicted N-terminus: Met

  • Molecular Characterization

    *The isotype control of empty/mock VLP (Cat. No. VLP-N5213) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.

    2. Synthesis Process

      Envelope virus-like particles (eVLPs) are produced by co-expressing target membrane proteins with viral structural proteins in mammalian cells, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and strong immunogenicity making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Formulation

    The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

    Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping and Storage

    This product is supplied and shipped on dry ice.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 12 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Kunden haben auch angesehen

Data Display

  • Bioactivity-ELISA

     NY-ESO-1 TCR & CD3E & CD3D & CD3G & CD3Z ELISA

    Immobilized Human NY-ESO-1 TCR & CD3 Full Length Protein Complex (VLP) (Cat. No. NYZ-H5213) at 5 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CD3 Antibody, Mouse IgG2a (Clone: OKT3), premium grade (Cat. No. CDE-M120a) with a linear range of 2-31 ng/mL (QC tested).

    Protocol
  •  NY-ESO-1 TCR & CD3E & CD3D & CD3G & CD3Z ELISA

    Immobilized Human NY-ESO-1 TCR & CD3 Full Length Protein Complex (VLP) (Cat. No. NYZ-H5213) at 1 μg/mL (100 μL/well) can bind Anti-KLK2×CD3 Antibody (Pasritamig Biosimilar) with a linear range of 0.2-250 ng/mL (Routinely tested).

    Protocol

User Reviews
Publish Comment

Background Introduction

Cluster of Differentiation 3 (CD3) is a pivotal multimeric T cell co-receptor complex essential for adaptive immune responses. Composed of epsilon (ε), gamma (γ), delta (δ), and zeta (ζ) polypeptide chains forming three distinct dimers (εγ, εδ, ζζ), CD3 non-covalently associates with the T-cell receptor (TCR) to establish the critical TCR/CD3 receptor complex on T cell surfaces. Structurally, CD3 proteins belong to the immunoglobulin superfamily, featuring a transmembrane domain, an N-terminal extracellular region with immunoglobulin-like domains, and cytoplasmic tails embedded with immunoreceptor tyrosine-based activation motifs (ITAMs). These ITAMs are fundamental for initiating signal transduction upon T cell receptor engagement, thereby activating both CD4+ T helper and CD8+ cytotoxic T cells. As a defining marker of the T cell lineage, CD3's central role in T cell activation makes its modulation, via stimulating or blocking antibodies, a promising therapeutic avenue for conditions like organ transplant rejection and autoimmune diseases.

Frontier Progress

 
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Kunden haben auch angesehen
  • Data Display
  • User Reviews
  • Hintergrund
Kontaktieren Sie uns